Biopharma Gains Lift Health Care as Breadth Offsets Testing Drag

The Health Care sector saw positive breadth on Tuesday, September 22, with 67.9% of its members advancing. The Health Care Select Sector SPDR Fund (XLV), an exchange-traded fund tracking the sector, closed +0.5% at $169.91, while the cap-weighted sector finished +0.6%. Across the stocks EasyAlpha grades in the sector, companies graded A or B represent 50.7% of the fund's weight. Sector performance was led by pharmaceutical and biotechnology holdings: Moderna Inc closed +5.6% as its stock continued to gain ground, while Amgen Inc closed +4.3% after announcing positive Sjögren's trial results.

The session's main headwind emerged in the medical laboratory industry. Quest Diagnostics Incorporated closed -4.2% after preliminary Medicare payment schedules proposed fee cuts averaging about 16% for laboratory tests, with reductions capped at 15% annually beginning in 2027. The proposal created selling pressure across commercial diagnostics providers facing lower reimbursement rates.

Despite the weakness in diagnostics, broader participation remained resilient. The equal-weighted sector move stood at +0.8%, outpacing the cap-weighted return of +0.6%. When equal-weighted returns exceed cap-weighted performance, it indicates that mid-sized and smaller industry constituents contributed more to the session than the heaviest index weights alone.

Across the wider equity market, 5 of the 11 sectors rose. As the sector's primary vehicle, XLV deploys $43.9 billion across these healthcare leaders with an expense ratio of 0.08%. The day's biopharma strength illustrates how clinical pipeline progress can support the sector through regulatory headwinds, helping keep the fund at +24.4% over the past twelve months and +17.3% over the past six months despite sitting at -2.7% over the past month.